Cannabis + Alcohol on Impairment
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores how cannabis and alcohol, both alone and together, affect feelings and behaviors. Researchers test different doses to determine how each combination impacts impairment. Participants join one of several groups involving various doses of cannabis and alcohol, or placebos (fake treatments). Those who have used both cannabis and alcohol together at least once in the past year and have experienced binge drinking at least twice in the last 90 days might be a good fit for this study. As a Phase 1 trial, this research focuses on understanding how these substances work in people, offering an opportunity to contribute to groundbreaking insights.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it excludes those using certain drugs or medications that could affect safety. It's best to discuss your specific medications with the trial staff.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that using cannabis and alcohol together can amplify their effects, leading to more noticeable impairment. One study found that even low doses of cannabis (10mg THC) can cause feelings of being "high" or paranoid, even without alcohol. Mixing cannabis with alcohol can intensify these feelings, increasing impairment and potentially leading to risky behaviors or accidents.
High doses of cannabis (25mg THC) can cause short-term issues like paranoia or temporary mental problems. These effects worsen when combined with even small amounts of alcohol, possibly causing dizziness or nausea. People may also behave unusually when using both substances together.
Overall, combining cannabis and alcohol increases the risk of dizziness, sweating, or nausea. It is important to be aware of these risks when considering participation in a clinical trial involving these substances.12345Why are researchers excited about this trial's treatments?
Researchers are excited about this trial because it explores how cannabis and alcohol interact to affect impairment, which is not well understood. Unlike traditional studies that focus on alcohol or cannabis alone, this investigation looks at how different doses of THC and alcohol together influence cognitive and motor functions. The trial includes unique combinations, such as high dose cannabis with low dose alcohol, to see how varying levels impact impairment. By understanding these interactions, the trial could provide insights into safer consumption guidelines and inform public health recommendations.
What evidence suggests that this trial's treatments could be effective for impairment?
Research shows that using cannabis and alcohol together impairs individuals more than using either alone. This trial will explore various combinations of cannabis and alcohol. Participants in different arms will receive either low or high doses of cannabis with either low-dose alcohol or placebo alcohol. Studies have found that this combination severely affects driving skills. Even at low doses, mixing cannabis with alcohol increases feelings of intoxication and stimulation. One study found that high doses of both substances can seriously affect memory and attention. These findings suggest that combining cannabis and alcohol significantly impacts behavior and perception.16789
Who Is on the Research Team?
Tory Spindle, PhD
Principal Investigator
Johns Hopkins University
Are You a Good Fit for This Trial?
Participants must be healthy adults aged 21-55, not pregnant or nursing, with a BMI of 19-36 kg/m2. They should have engaged in binge drinking at least twice in the past 90 days and used cannabis within the last year but no more than twice weekly over the past three months.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants complete 7 outpatient drug administration sessions with self-administration of oral cannabis and alcohol
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Alcohol
- Cannabis
Alcohol is already approved in United States, European Union, Canada, Japan, China, Switzerland for the following indications:
- None (not approved as a therapeutic agent)
- None (not approved as a therapeutic agent)
- None (not approved as a therapeutic agent)
- None (not approved as a therapeutic agent)
- None (not approved as a therapeutic agent)
- None (not approved as a therapeutic agent)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Johns Hopkins University
Lead Sponsor
National Institute on Drug Abuse (NIDA)
Collaborator